Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04988412
Other study ID # VIST TO-COSKIN 01-2021
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 11, 2021
Est. completion date April 21, 2022

Study information

Verified date January 2023
Source VIST - Faculty of Applied Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the randomized, double-blind, placebo-controlled, one-period effectiveness study is to compare the effects of multiple-dose 12 weeks daily dietary supplementation with 10 g collagen alone or 5 g or 10 g of collagen in combination with MSM on skin in healthy human subjects in comparison to placebo product. The main objective is to show that test products have beneficial effects on dermis density, and also on other skin parameters and to investigate differences in the effects among test products.


Description:

This is a double-blind, randomized, placebo-controlled four-way study comparing the efficacy of multiple-dose dietary intake of three test products on skin parameters, that will be conducted in Slovenia in one research center. The study will be performed on 109 adult women, between the ages 40 and 65 years and will include daily dietary supplementation over 12-weeks period. Subjects will be divided in four study groups . Test group 1 (TG1) will receive investigational product 1 (IP1, daily dose 25 mL: collagen 5 g, MSM: 1,5 g, vitamin C: 80 mg), test group 2 (TG2) will receive investigational product 2 (IP2, daily dose 25 mL: collagen 10 g, vitamin C: 80 mg), test group 3 (TG3) will receive investigational product 3 (TP3, daily dose 25 mL: collagen 10 g, MSM: 1,5 g, , vitamin C: 80 mg) and the placebo group (PG) will receive placebo product without those active ingredients (25 mL: 0 g collagen, 0 g MSM). Participants will test continuous administration of placebo or investigational products for 12 weeks in order to demonstrate and assess multiple-dose effects. Their influence on skin appendages via self-evaluations questionnaires will also be assessed.


Recruitment information / eligibility

Status Completed
Enrollment 109
Est. completion date April 21, 2022
Est. primary completion date February 21, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 65 Years
Eligibility Inclusion criteria: - Caucasian female volunteers aged between 40 and 65 years at the time of the signature of Informed consent form (ICF), - Signed Informed consent form (ICF), - Fitzpatrick skin phototypes I-IV, - Signs of skin aging, - In good general health condition, - Body mass index (BMI) < 35 - Willingness to avoid a consumption of any food supplements containing methylsulfonylmethane (MSM), antioxidants, collagen and other protein-based food supplements during the study, - Willingness to follow all study procedures and keeping a diary during the study (to follow their compliance and palatability). - Willingness to maintain their living habits and to not begin or change any estrogen or progesterone therapies, - Willingness to avoid shaving/depilation of their arms during the study, - Willingness not to change cosmetic treatment routine during the study, - Willingness to avoid rejuvenation treatments during the study. Exclusion criteria: - Pregnancy or breastfeeding, - Known or suspected allergy to any ingredient of the tested products, - Changes in dietary habits and dietary supplementation in the last three months prior to inclusion, - Regular use of food supplements containing MSM, antioxidants, collagen or other protein-based food supplements in the last three months prior to inclusion, - Veganism, - Changes in cosmetic facial and body care routine in the last month prior to inclusion, - Diagnosed and uncontrolled/unregulated disease, - Any clinically significant history of serious metabolic disease, digestive tract disease, liver disease, kidney disease, hematological disease, - Intake of drugs with any impact on skin reactions (e.g., glucocorticoids, antihistamines, and immunomodulators), - Any clinically significant acute or chronic skin diseases, - Skin pigmentation disorders on measuring sites, - Anticipated sunbathing or solarium visits before or during the study, - Invasive rejuvenation treatments (e.g. needle rollers, needle mesotherapy, deep/medium-deep chemical peels, laser therapy etc.) in the last 4 months prior to study entry, - Non-invasive rejuvenation treatments (e.g. radiofrequency, electrotherapy, ultrasound, intense pulsed light therapy (IPL)) in the last month prior to study entry, - Shaving/depilation of the arms in the last 14 days before inclusion, - Mental incapacity that precludes adequate understanding or cooperation.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Investigational product 1
Test group 1 will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
Placebo syrup
Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 12 weeks.
Investigational product 2
Test group 2 will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
Investigational product 3
Test group 3 will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.

Locations

Country Name City State
Slovenia Higher School of Applied Sciences, Institute of Cosmetics Ljubljana

Sponsors (3)

Lead Sponsor Collaborator
VIST - Faculty of Applied Sciences Slovenian Research Agency, Tosla d.o.o.

Country where clinical trial is conducted

Slovenia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of dermis density from baseline in all test groups in comparison to placebo group after 12 weeks of dietary supplementation Significant change of dermis density from baseline in test groups, in comparison to placebo group after 12 weeks of dietary supplementation with study product is expected. Dermis density will be assessed through ultrasonographic dermis intensity measurement. Differences in change of dermis density between test groups under primary objective conditions will also be evaluated. 12 weeks
Secondary Change of wrinkle volume from baseline in test groups, in comparison to placebo group after 12 weeks of dietary supplementation Assessment of the effects of investigational product on periorbital wrinkles after 12 weeks of dietary supplementation will be done using topography measurements. Differences between test groups will also be evaluated. 12 weeks
Secondary Change of skin texture from baseline in test groups, in comparison to placebo group after 12 weeks of dietary supplementation For assessments of skin texture topography roughness measurements (Ra, Rq) will be performed. Significant changes from baseline in test groups, in comparison to placebo group after 12 weeks of dietary supplementation is expected. Differences between test groups will also be evaluated. 12 weeks
Secondary Change of skin hydration from baseline in test groups, in comparison to placebo group after 12 weeks of dietary supplementation Assessment of the effects of the investigational product on skin hydration after 12 weeks of dietary supplementation. Skin hydration measurements will be performed using conductance principle. Differences between test groups will also be evaluated. 12 weeks
Secondary Change of TEWL from baseline in test groups, in comparison to placebo group after 12 weeks of dietary supplementation Assessment of the effects of investigational product on transepidermal water loss (TEWL) after 12 weeks of dietary supplementation. TEWL measurements will be performed using open chamber principle.Differences between test groups will also be evaluated. 12 weeks
Secondary Change of dermis thickness from baseline in test groups, in comparison to placebo group after 12 weeks of dietary supplementation Significant change of dermis thickness from baseline in test group, in comparison to placebo group after 12 weeks of dietary supplementation with study product is expected. Dermis density will be assessed using ultrasonography. Differences between test groups will also be evaluated. 12 weeks
Secondary Change of skin elasticity from baseline in test groups, in comparison to placebo group after 12 weeks of dietary supplementation For assessments of elasticity viscoelasticity measurements will be performed. Significant changes from baseline in test groups, in comparison to placebo group after 12 weeks of dietary supplementation is expected. Differences between test groups will also be evaluated. Along viscoelasticity the measurement sinchronosusly gives also retraction and Young modulus values, as well as U-values: Uf (final deformation), Ue (skin exstensibility), Uv (delayed distension), Ur (immediate retraction), Ua (total recovery). R5 (Ur/Ue) parameter will also be calculated. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT01984619 - Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles N/A
Completed NCT01713985 - Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck N/A
Recruiting NCT01586819 - Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A Phase 3
Completed NCT05254210 - Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device N/A
Completed NCT02604641 - Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin N/A
Completed NCT01460927 - TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides N/A
Completed NCT01519934 - A Retrospective Study to Evaluate the Effectiveness of the Ulthera System N/A
Completed NCT03811756 - The Effect of 12-week Dietary Intake of Syrup Containing CoQ10 and Collagen on Dermis Density and Other Skin Parameters N/A
Completed NCT02913547 - Silk'n HST for Wrinkle Reduction - Clinical Study Protocol N/A
Active, not recruiting NCT02019004 - A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles N/A
Completed NCT02340078 - A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Volume Plus Versus YVOIRE Volume in Nasolabial Fold Injection N/A
Completed NCT01283464 - Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles Phase 2
Completed NCT01034956 - Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections N/A
Completed NCT02425943 - Sculptra Aesthetic Post-Approval Study Phase 4
Recruiting NCT05847530 - Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions N/A
Enrolling by invitation NCT01847066 - Epidermal Delivery of Ani-Aging Ingredients N/A
Completed NCT01859611 - TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides N/A
Completed NCT01297634 - Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle Phase 4
Completed NCT05011461 - The Effect of Topical Almond Oil vs. Topical Retinol on The Appearance of Facial Wrinkles N/A
Completed NCT03460860 - Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging N/A